Veterinarian medicine is just one of Dr. Geert Vanden Bossoche’s many disciplines read below. Perhaps you should read the report. He’s one of the few people in the world that is able to put the pieces of the puzzle together.
Critique the specifics of the 45 page report. Then we can have some debate!!
Managing Director
VARECO
Sep 2012 - 2019
Europe
Independent vaccine consultant with a long- standing track record in Academia, Vaccine
Industry and Global Health (GH); providing support on vaccine project management as
well as advice, guidance and expert opinion on preclinical development of vaccines &
biologicals, from project selection up to IND. Assignments include prophylactic and
therapeutic vaccine projects in Human and Veterinary Vaccine Industry, Small Biotech,
Global Health organizations in the US or Europe
Head of the Vaccine Development Office
German Centre for Infection Research (DZIF)
Aug 2017 - Dec 2017
Cologne, Germany
Spearheading a portfolio of translational vaccine research projects, conducted at
German universities and research centres sponsored by DZIF. Holding overall
accountability for strategic alignment of translational infection research in support of
preclinical and early clinical testing. Developing a trans-academic translational network
for Vaccine development totaling eight universities and research organizations across
Germany.
Chief Innovation & Scientific Officer
Univac
Nov 2014 - Nov 2016
Huldenberg
II founded Univac as inventor of a new vaccine technology which I subsequently further
developed as CSO of the Company. The technology enables the development of
universal vaccines educating the host immune system to redirect immune targeting
away from canonical antigens to a widely divergent spectrum of vitally vulnerable
pathogen-derived ‘self-mimicking’ antigens, irrespective of MHC polymorphism.
Although ‘non-self’ and exposed on the surface of infected or pathologically altered
cells…
Program Manager
Global Alliance for Vaccines and Immunization (GAVI)
Mar 2015 - Mar 2016
Geneva Area, Switzerland
During my term at GAVI, I coordinated GAVI’s Ebola Vaccine Program and contributed
to the implementation of an integrated vaccine work plan in collaboration with Global
Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA)
and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine
candidate(s) that suitably meet the requirements for use in an Ebola epidemic. In this
capacity, I also contributed to several workshops aimed at proposing…
Show more
DVM, PhD, adjunct professor
Positions in Academia
Sep 1980 - Sep 2015
Belgium - Germany
- Training in Veterinary Medicine at the faculty Notre-Dame-de-la-Paix and the State
University of
Ghent (1980-1983)
- Doctoral degree in Veterinary Medicine from State University of Ghent (1983)
- Postdoctoral training in Equine Medicine and Surgery at the Free University of Berlin,
Germany
(1984-1987)
- Postdoctoral Fellowship in Virology at James A. Baker Institute for Animal Health,
Cornell
University, Ithaca, NY 14850, USA (Sept 1990- mid 1991)
- Research…
Senior Program Officer, Global Health, Vaccine Discovery
Bill & Melinda Gates Foundation (BMGF)
May 2008 - Jun 2011
Seattle, Washington 98102, USA
Responsible for operating Vaccine Programs (e.g., HIV-1, Malaria, TB, Polio…) and
establishing international product development partnerships for immune interventions
in Global Health (e.g., with Academia, Biotech Industry, NIH, Welcome Trust, WHO,
PATH). Coordinating and spearheading international collaborations and consortia on
innovative vaccine approaches and steering multidisciplinary vaccine initiatives
Global Project Director Influenza Vaccines
Solvay Biologicals
Jul 2007 - May 2008
Weesp, the Netherlands
Responsible for leading the operational aspects of an interdisciplinary project team
including the planning and implementation of adjuvanted Influenza vaccines that enable
dose sparing. Implementation of commercial-scale production of cell-based methods
and expansion of Influenza vaccine production capacity such as to meet DHSS (U.S.
Department of Human Health Services) contractual requirements (Pandemic Influenza
Preparedness Plan)
Director, Research Program Leader and Head of Adjuvants
Novartis Vaccines & Diagnostics
Aug 2006 - Jul 2007
Siena, Italy & Emeryville, USA
Vaccine Research Program/Adjuvant Program responsibilities:
- Project leader of NVD’s RSV vaccine project (Respiratory Syncytial Virus)
- Coordinator of preclinical activities on combined seasonal RSV-Influenza vaccine for
elderly & high risk adults
- Responsible for defining and shaping the scope and strategy of NVD’s adjuvant and
vaccine delivery technologies including management of NVD’s adjuvant portfolio,
opportunity…
Head of Adjuvant Technologies and Alternative Deliveries, R&D
GlaxoSmithKline Biologicals
May 2001 - May 2006
Rixensart, Belgium
- Research Program Leader on Vaccine Formulation Development & Alternative
Deliveries and in charge of biophysical characterization activities on adjuvanted vaccine
formulations.
- Coordination and follow-up of extramural contracts & collaboration agreements on
new immunization strategies and innovative vaccine adjuvant, delivery or formulation
technologies (e.g., co-delivery, mucosal, subcutaneous, intradermal immunization)
- Development and validation of vaccine and…
GSK Biologicals
o Senior Project Leader ‘Adolescent Vaccine Projects’
Jun 1998 - May 2001
Rixensart, Belgium
Major responsibilities:
Project Management on Raw Material Traceability (RAMATRA) and vaccine projects in
Late Development, e.g., Herpes Simplex Virus type 2, Hepatitis B, Streptococcus
Pneumoniae and Enterotoxic Escherichia Coli (in collaboration with SBL Vaccines,
Sweden)
o New Biotech Vaccine Development and QC-QA Manager
Feb 1995 - May 1998
Rixensart, Belgium
Major responsibilities (3 direct reports; 6 technicians):
- Management and coordination of vaccine product development, optimization as
well as validation of analytical methods in accordance with regulatory requirements
or guidelines and vaccine marketing constraints
- Budget management of all activities related to QC assay development
- Transfer from R&D and further development of new QC-relevant characterization
techniques on new vaccine candidates (e.g., HSV-2 vaccine, Lyme disease vaccine);
contacts with national/international regulatory and health authorities (e.g., FDA,
NIBSC, IHE, WHO,…) on technical dossiers; active participation in pre-IND meetings